Full history for every metric is available with a Kvantra account
Probiotec Limited (PBP.AX)
Key financial summary
Financials in AUD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | AUD m | 76 | 73 | 107 | 121 | 182 | 214 | 221 |
| Operating profit | AUD m | 21 | 19 | |||||
| Net profit | AUD m | 4 | 4 | 4 | 5 | 14 | 11 | 9 |
| EPS reported | AUD | 0.13 | 0.10 | |||||
| Operating cashflow per share | AUD | 0.21 | 0.21 | |||||
| Capex per share | AUD | 0.12 | 0.12 | |||||
| FCF per share | AUD | 0.09 | 0.09 | |||||
| Free cash flow | AUD m | 7 | 5 | |||||
| Net debt | AUD m | 74 | 39 | |||||
| Book value equity | AUD m | 87 | 88 | |||||
| Book value per share | AUD | 1.05 | 1.05 | |||||
| Number of shares | m | 83.02 | 83.87 | |||||
| DPS (TTM paid) | AUD | 0.11 | 0.11 |
Financial summary
Financials in AUD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 21.54 | - | |||||
| P/B LTM | x | 2.61 | 2.74 | |||||
| P/S LTM | x | 1.06 | 1.10 | |||||
| P/FCF LTM | x | 32.42 | 50.39 | |||||
| EV/EBITDA LTM | x | 8.52 | 8.12 | |||||
| EV/Sales LTM | x | 1.41 | 1.27 | |||||
| Earnings Yield LTM | % | 4.64% | 4.55% | |||||
| FCF Yield | % | 3.08% | 1.98% | |||||
| Quality | ||||||||
| ROE | % | 12.64% | 13.26% | |||||
| ROIC | % | 7.55% | 7.55% | |||||
| Operating margin | % | 9.69% | 9.69% | |||||
| Gross margin | % | 28.78% | 28.78% | |||||
| FCF/Sales | % | 3.28% | 3.28% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | -23.53% | -43.25% | |||||
| Sales Growth YoY | % | +17.39% | +8.47% | |||||
| Net Income Growth YoY | % | -19.61% | -41.01% | |||||
| FCF Growth | % | -44.22% | -49.51% | |||||
| Operating Profit Growth | % | +5.60% | -9.66% | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 2.32% | 3.61% | |||||
| Dividend Growth | % | +65.38% | - | |||||
| Payout Ratio | % | 47.98% | 47.98% | |||||
| FCF/Debt | x | 0.08 | 0.06 | |||||
| Net Debt/EBITDA | x | 2.09 | 2.09 | |||||
| EBIT/Net interest | x | 3.59 | 3.59 | |||||
| Net debt/market cap | % | 32.43% | 15.98% | |||||
| Net debt/Equity | x | 0.85 | 0.44 | |||||
| Gross debt/equity | x | 1.01 | 0.97 | |||||
Company overview
Established in 1996 and based in Laverton North, Australia, Probiotec Limited is involved in the creation, production, packaging, and distribution of pharmaceuticals, consumer healthcare products, and fast-moving consumer goods both domestically and internationally. The company delivers extensive contract manufacturing solutions, covering the production of various formats including solid dose tablets, capsules, liquids, creams, gels, ointments, suspensions, and powders, alongside services like tablet coating, blister packing, and spray manufacturing. Furthermore, Probiotec offers analytical and stability testing, assists with new product formulation and trials, conducts continuous research and development, and provides a wide array of packaging options for human and animal nutrition items. It also manufactures and exports a selection of nutraceuticals and key functional ingredient raw materials.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Probiotec Limited (PBP.AX)
Established in 1996 and based in Laverton North, Australia, Probiotec Limited is involved in the creation, production, packaging, and distribution of pharmaceuticals, consumer healthcare products, and fast-moving consumer goods both domestically and internationally. The company delivers extensive contract manufacturing solutions, covering the production of various formats including solid dose tablets, capsules, liquids, creams, gels, ointments, suspensions, and powders, alongside services like tablet coating, blister packing, and spray manufacturing. Furthermore, Probiotec offers analytical and stability testing, assists with new product formulation and trials, conducts continuous research and development, and provides a wide array of packaging options for human and animal nutrition items. It also manufactures and exports a selection of nutraceuticals and key functional ingredient raw materials.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free